Erwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.

The global Erwinia L-Asparaginase market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Erwinia L-Asparaginase volume and value at global level, regional level and company level. From a global perspective, this report represents overall Erwinia L-Asparaginase market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Erwinia L-Asparaginase in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Erwinia L-Asparaginase manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Jazz Pharmaceuticals
Shire
Medac GmbH
Kyowa Hakko Kirin
Qianhong Bio-pharma
Taj Pharmaceuticals
Mingxing Pharma
Exova (SL Pharma)
United Biotech

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Escherichia Coli
Erwinia Chrysanthemi
Pegylated

Segment by Application
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Other